These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

369 related items for PubMed ID: 27928636

  • 1. Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
    Chang YM, Tsai SC, Shiao CC, Liou HH, Yang CL, Tung NY, Hsu KS, Chen IL, Liu MC, Kao JL, Jhen RN, Huang YT.
    Clin Exp Nephrol; 2017 Oct; 21(5):908-916. PubMed ID: 27928636
    [Abstract] [Full Text] [Related]

  • 2. The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
    Soriano S, Ojeda R, Rodríguez M, Almadén Y, Rodríguez M, Martín-Malo A, Aljama P.
    Clin Nephrol; 2013 Jul; 80(1):17-22. PubMed ID: 23391319
    [Abstract] [Full Text] [Related]

  • 3. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
    Toida T, Fukudome K, Fujimoto S, Yamada K, Sato Y, Chiyotanda S, Kitamura K.
    Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
    [Abstract] [Full Text] [Related]

  • 4. Design and baseline characteristics of the LANDMARK study.
    Ogata H, Fukagawa M, Hirakata H, Kaneda H, Kagimura T, Akizawa T, LANDMARK Study Group.
    Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
    [Abstract] [Full Text] [Related]

  • 5. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
    Isakova T, Barchi-Chung A, Enfield G, Smith K, Vargas G, Houston J, Xie H, Wahl P, Schiavenato E, Dosch A, Gutiérrez OM, Diego J, Lenz O, Contreras G, Mendez A, Weiner RB, Wolf M.
    Clin J Am Soc Nephrol; 2013 Jun; 8(6):1009-18. PubMed ID: 23471131
    [Abstract] [Full Text] [Related]

  • 6. Phosphate control in reducing FGF23 levels in hemodialysis patients.
    Rodelo-Haad C, Rodríguez-Ortiz ME, Martin-Malo A, Pendon-Ruiz de Mier MV, Agüera ML, Muñoz-Castañeda JR, Soriano S, Caravaca F, Alvarez-Lara MA, Felsenfeld A, Aljama P, Rodriguez M.
    PLoS One; 2018 Jun; 13(8):e0201537. PubMed ID: 30086150
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis.
    Watanabe K, Fujii H, Kono K, Goto S, Nishi S.
    BMC Cardiovasc Disord; 2020 Jan 30; 20(1):39. PubMed ID: 32000687
    [Abstract] [Full Text] [Related]

  • 8. Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis.
    Fujii H, Kono K, Nakai K, Goto S, Nishii T, Kono A, Nishi S.
    Calcif Tissue Int; 2018 Mar 30; 102(3):310-320. PubMed ID: 29058057
    [Abstract] [Full Text] [Related]

  • 9. Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
    Ureña-Torres P, Prié D, Keddad K, Preston P, Wilde P, Wan H, Copley JB.
    BMC Nephrol; 2014 May 05; 15():71. PubMed ID: 24885942
    [Abstract] [Full Text] [Related]

  • 10. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.
    Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, Mochida Y, Maesato K, Ishioka K, Moriya H, Hidaka S.
    J Cardiovasc Pharmacol Ther; 2013 Sep 05; 18(5):439-46. PubMed ID: 23615577
    [Abstract] [Full Text] [Related]

  • 11. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
    Shigematsu T, Negi S, COLC Research Group.
    Nephrol Dial Transplant; 2012 Mar 05; 27(3):1050-4. PubMed ID: 21771755
    [Abstract] [Full Text] [Related]

  • 12. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
    Prajapati VA, Galani VJ, Shah PR.
    Saudi J Kidney Dis Transpl; 2014 May 05; 25(3):530-8. PubMed ID: 24821148
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.
    Zhai CJ, Yang XW, Sun J, Wang R.
    Int Urol Nephrol; 2015 Mar 05; 47(3):527-35. PubMed ID: 25399356
    [Abstract] [Full Text] [Related]

  • 14. Lanthanum carbonate: a postmarketing observational study of efficacy and safety.
    Rombolà G, Londrino F, Corbani V, Falqui V, Ardini M, Zattera T, Liguria and Toscana Lanthanum Experience (LITOLAE) Group.
    J Nephrol; 2012 Mar 05; 25(4):490-6. PubMed ID: 22476966
    [Abstract] [Full Text] [Related]

  • 15. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
    Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG.
    Nephrology (Carlton); 2011 Mar 05; 16(3):290-8. PubMed ID: 21342323
    [Abstract] [Full Text] [Related]

  • 16. Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study.
    Zhang C, Wang S, Zhao S, Zhang X.
    Medicine (Baltimore); 2017 Nov 05; 96(45):e8664. PubMed ID: 29137107
    [Abstract] [Full Text] [Related]

  • 17. Effect of lanthanum carbonate on the progression of coronary artery calcification in hemodialysis patients: A meta-analysis of randomized controlled trials.
    Xu JP, Zeng RX, Liao PD, Zhang MZ.
    Hemodial Int; 2022 Apr 05; 26(2):223-233. PubMed ID: 34897963
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial.
    Wada K, Wada Y.
    Ther Apher Dial; 2014 Aug 05; 18(4):353-60. PubMed ID: 24417760
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.